NCT02241187 is a NA clinical trial of PEGPH20 in Pancreatic Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Who is sponsoring NCT02241187?

NCT02241187 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT02241187?

Interventions in NCT02241187: PEGPH20, Cetuximab, DW & DCE-MRI, blood draws.

What condition does NCT02241187 study?

NCT02241187 studies Pancreatic Cancer.

Is NCT02241187 still recruiting?

NCT02241187 is currently completed. Last updated 27 September 2017.

Are results published for NCT02241187?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-09-27 · How we verify

NCT02241187

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

Completed NA Results posted Last updated 27 September 2017

What this trial tests

NA trial testing PEGPH20 in Pancreatic Cancer in 2 participants. Completed in 13 September 2016.

Timeline

12 September 2014

Primary endpoint
13 September 2016

13 September 2016

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	12 September 2014
Primary completion	13 September 2016
Estimated completion	13 September 2016
Sites	1 location across United States

Drugs / interventions tested

PEGPH20 — full drug profile →
Cetuximab (cetuximab) — full drug profile →
DW & DCE-MRI
blood draws — full drug profile →

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study has several purposes. DCE-MRI will be used to image the tumor. Safety of cetuximab given before surgery will be studied. Cetuximab delivery to the tumor will be studied. In Stage 2 of this study, the safety of cetuximab and PEGPH20 given before surgery will be studied. Also, the effects of PEGPH20 on tumors will be studied.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy.
Henke E, Nandigama R, Ergün S. · · 2019 · cited 798× · PMID 32118030 · DOI 10.3389/fmolb.2019.00160
Targeting the tumor stroma for cancer therapy.
Xu M, Zhang T, Xia R, Wei Y, et al · · 2022 · cited 195× · PMID 36324128 · DOI 10.1186/s12943-022-01670-1
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.
Zhang T, Ren Y, Yang P, Wang J, et al · · 2022 · cited 142× · PMID 36284087 · DOI 10.1038/s41419-022-05351-1
Beyond matrix stiffness: targeting force-induced cancer drug resistance.
Kalli M, Poskus MD, Stylianopoulos T, Zervantonakis IK. · · 2023 · cited 112× · PMID 37558577 · DOI 10.1016/j.trecan.2023.07.006
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.
Knudsen ES, O'Reilly EM, Brody JR, Witkiewicz AK. · · 2016 · cited 91× · PMID 26385075 · DOI 10.1053/j.gastro.2015.08.056
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue.
Longo V, Brunetti O, Gnoni A, Cascinu S, et al · · 2016 · cited 74× · PMID 27462915 · DOI 10.18632/oncotarget.10765
Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy.
Parkin A, Man J, Timpson P, Pajic M. · · 2019 · cited 40× · PMID 31330086 · DOI 10.1111/febs.15011
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.
Vacchelli E, Pol J, Bloy N, Eggermont A, et al · · 2015 · cited 32× · PMID 25949870 · DOI 10.4161/2162402x.2014.985940

Verify or expand the search:

Other trials of PEGPH20

Trials testing the same drug.

NCT03979066 — Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma · Phase 2 · terminated
NCT03267940 — Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS an · Phase 1 · terminated
NCT03193190 — A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenoca · Phase 1, PHASE2 · completed
NCT02563548 — A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluron · Phase 1 · completed
NCT02487277 — PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma · Phase 2 · terminated

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02241187 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 27 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02241187.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing